Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy.

ABSTRACT:

Objectives

Pediatric cancer survivors are at increased risk for vaccine-preventable diseases due to treatment-related immunosuppression. This study aimed to assess serological status for measles, mumps, and rubella (MMR) following chemotherapy and identify factors associated with antibody loss.

Results

Fifty-four pediatric cancer survivors (mean age 12.5 years) were evaluated at a median of 2.5 years (IQR 1.2, 5.4) after completing chemotherapy. All participants had received at least one MMR dose before their cancer diagnosis and had completed treatment at least six months prior. Overall, 43 patients (79.6%) were seronegative for at least one MMR component. Seronegativity was highest for measles (64.8%), followed by mumps (55.6%) and rubella (35.2%). Measles seronegativity w

SUBMITTER: Nakasuwan K 

PROVIDER: S-EPMC12831313 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature